晶泰控股-P(02228.HK) 公布,完成对或然生物(Alternative Bio)的战略投资,并建立深度研发合作。双方正基于或然生物在全球未满足的临床需求领域所发现的First-in-Class(首创新药)靶点,共同推进创新药物研发。晶泰科技首席科学官张佩宇认为或然生物在蛋白翻译调控及疾病机制解析领域的前沿突破,为一系列突破性的靶点发现提供全新可能;期待与世界级科学家的紧密协作,充分发挥...
Source Link晶泰控股-P(02228.HK) 公布,完成对或然生物(Alternative Bio)的战略投资,并建立深度研发合作。双方正基于或然生物在全球未满足的临床需求领域所发现的First-in-Class(首创新药)靶点,共同推进创新药物研发。晶泰科技首席科学官张佩宇认为或然生物在蛋白翻译调控及疾病机制解析领域的前沿突破,为一系列突破性的靶点发现提供全新可能;期待与世界级科学家的紧密协作,充分发挥...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.